Can cannabis help inflammatory bowel disease and Crohn's disease?

The GI tract has one of the highest densities of CB1 and CB2 receptors in the body, and the ECS plays a key role in regulating gut motility, inflammation, and intestinal permeability. This provides strong biological rationale for cannabis in IBD. Clinical evidence: A 2013 Israeli RCT (Naftali et al., n=21) found cannabis cigarettes induced clinical remission in 45% of Crohn's patients vs. 10% placebo — but did not reduce inflammatory markers (CRP, calprotectin), suggesting symptom relief without true anti-inflammatory effect. A 2021 follow-up RCT found similar results. For ulcerative colitis, a 2018 RCT found CBD capsules did not improve remission rates. Patient surveys consistently show high rates of self-reported symptom improvement (pain, nausea, appetite, stool frequency). The disconnect between symptom relief and objective inflammation reduction is a critical finding — cannabis may mask symptoms without treating underlying disease, potentially delaying effective treatment.